Semaglutide in Preventing Proteinuria in CKD

Background: Why Proteinuria Matters in CKD

Mechanism: How Does Semaglutide Reduce Proteinuria?

1. Hemodynamic Effects

• GLP-1 receptors are expressed in the kidney, particularly in tubular cells and the glomerulus.
• Semaglutide reduces intraglomerular hypertension by decreasing afferent arteriolar tone, similar (but complementary) to the mechanism of ACE inhibitors/ARBs.
• It promotes natriuresis, reducing tubuloglomerular feedback pressure.

2. Anti-inflammatory and Anti-fibrotic Actions

• GLP-1 receptor activation suppresses NF-κB signaling, reducing pro-inflammatory cytokines (TNF-α, IL-6) in the kidney.
• Inhibits TGF-β-mediated fibrosis and podocyte apoptosis - key pathological drivers of proteinuria.
• Reduces oxidative stress at the glomerular level.

3. Metabolic and Weight-Loss Effects

• Substantial weight loss (10-15% body weight) reduces obesity-related glomerular hyperfiltration and glomerulosclerosis - a mechanism relevant even in non-diabetic CKD.
• Blood pressure reduction (systolic BP ~5 mmHg) independently lowers proteinuria.
• In diabetic CKD, improved glycemic control reduces advanced glycation end-products that damage the glomerular basement membrane.

4. Direct Glomerular Protection

• GLP-1 receptor signaling protects podocytes (which are integral to the glomerular filtration barrier) from injury and loss, directly reducing albumin leak.

Clinical Evidence

FLOW Trial (2024) - The Landmark RCT

• 24% reduction in major kidney disease events (HR 0.76; 95% CI 0.66-0.88)
• 40% reduction in UACR at 104 weeks vs. 12% in placebo group
• 29% reduction in cardiovascular death
• Slowed eGFR decline by 1.16 mL/min/1.73m²/year
• All-cause mortality reduced: 12.8% vs. 15.8% (NNT ~34 over 3.4 years)

SUSTAIN-6 (Earlier Evidence)

• 36% reduction in new or worsening nephropathy vs. placebo in T2DM patients.
• Treatment ratio for UACR: 0.74 (P <0.001); 46% reduction in new-onset macroalbuminuria.

Non-Diabetic CKD - Key RCT (Apperloo et al., Nature Medicine 2025, PMID 39455729)

• Mean UACR at baseline: 251 mg/g; mean eGFR: 65 mL/min/1.73m²
• Etiologies: chronic glomerulonephritis, hypertensive CKD
• Primary outcome: -52.1% reduction in UACR at 24 weeks (95% CI -65.5 to -33.4; P <0.0001) vs. placebo
• This confirms the anti-proteinuric effect is independent of diabetes and glycemic control.

Systematic Review & Meta-Analysis (Elganyny et al., Clin Ter 2026, PMID 42340790)

• Significant eGFR improvement (eGFR >30 mL/min/1.73m² increasing from baseline in all studies)
• Significant weight loss and BP reduction
• Semaglutide well-tolerated including in dialysis-dependent patients

Meta-Analysis of 8 Major RCTs (GLP-1 class data, 68,572 patients)

• GLP-1 RAs reduced worsening kidney function: RR 0.84 (95% CI 0.77-0.91)
• Reduced persistent macroalbuminuria: RR 0.75 (95% CI 0.69-0.83)
• Consistent across subgroups of eGFR, albuminuria, sex, and BMI

Regulatory Status (2025-2026)

• FDA (January 2025): Approved semaglutide (Ozempic) for reducing risk of sustained eGFR decline, ESKD, and cardiovascular death in adults with T2DM + CKD - the first GLP-1 RA with this indication.
• Health Canada (August 2025): Expanded Ozempic indication for kidney event risk reduction in T2DM.

Current Guideline Positioning

• Metformin + SGLT2i = first-line for T2DM + CKD
• GLP-1 RAs (including semaglutide) = second-line or for patients unable to tolerate SGLT2i, or for additional cardiorenal protection - Comprehensive Clinical Nephrology, 7th Ed., p. 1181
• ADA 2025: For T2DM + CKD (eGFR <60 or ACR ≥3 mg/mmol) on max-tolerated ACEi/ARB, recommend SGLT2i or GLP-1 RA with demonstrated kidney benefit
• The 2025 KDIGO commentary now supports broader use of GLP-1 RAs as organ-protective therapies, potentially even as first-line agents alongside SGLT2i

Practical Points

Key Takeaway